Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,237 shares of the biopharmaceutical company's stock after selling 5,633 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in Gilead Sciences were worth $1,038,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA lifted its stake in Gilead Sciences by 0.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company's stock worth $5,887,000 after acquiring an additional 522 shares during the last quarter. Seven Eight Capital LP purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $525,000. AE Wealth Management LLC grew its stake in shares of Gilead Sciences by 11.7% during the second quarter. AE Wealth Management LLC now owns 29,796 shares of the biopharmaceutical company's stock worth $2,044,000 after purchasing an additional 3,124 shares in the last quarter. Summit Trail Advisors LLC increased its holdings in Gilead Sciences by 37.7% in the second quarter. Summit Trail Advisors LLC now owns 17,105 shares of the biopharmaceutical company's stock valued at $1,174,000 after buying an additional 4,683 shares during the last quarter. Finally, Kowal Investment Group LLC raised its stake in Gilead Sciences by 4.2% in the second quarter. Kowal Investment Group LLC now owns 4,384 shares of the biopharmaceutical company's stock valued at $301,000 after buying an additional 176 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company's stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 456,234 shares of company stock valued at $42,130,461. Corporate insiders own 0.29% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on GILD shares. UBS Group upped their price objective on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target for the company. Royal Bank of Canada reissued a "sector perform" rating and set a $84.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Barclays upped their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a report on Thursday, November 7th. Finally, Mizuho lifted their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $97.96.

Gilead Sciences Price Performance

NASDAQ GILD traded up $0.19 during mid-day trading on Monday, hitting $91.84. The stock had a trading volume of 6,852,085 shares, compared to its average volume of 5,370,915. The company has a 50 day simple moving average of $91.75 and a 200 day simple moving average of $84.20. The company has a market cap of $114.46 billion, a price-to-earnings ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. The business's revenue for the quarter was up 7.0% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.